

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Weshington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/036,371	01/07/2002	Jon Bragi Bjarnason	P 284960 176US1-DIV	5545
75	590 08/06/2002			
Pillsbury Winthrop LLP Intellectual Property Group 1600 Tysons Boulevard			EXAMINER	
			PATTEN, PATRICIA A	
McLean, VA	22102		ART UNIT	PAPER NUMBER
			1651	И
			DATE MAILED: 08/06/2002	1

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/036,371	1/7/02	Biarnason, J.	P 284960 167US1-DIV

EXAMINER

Patten

ART UNIT PAPER NUMBER

1651 4

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1), (a)(2), (c) and (e). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicants are **required** to subunit a new paper copy and CRF encompassing **all** of the sequences, or alternatively to cancel the additional sequence and request transfer of the sequence disclosure from the parent file in response to this Office action for the response to be complete.

The following language is a sample of a paragraph that should be submitted in a separate paper to effect this transfer of the CRF.

The computer readable form in this application, [Serial Number], is identical with that filed in [Serial Number], filed [Date]. In accordance with 37 CFR 1.1821(e), please use the [first-filed, last-filed, or only (whichever is applicable)] computer readable form

filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is [included in the originally-filed specification of the instant application, or included in a separately filed preliminary amendment for incorporation into the specification (whichever is applicable)].

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Examiner Patricia Patten Art Unit 1651, whose telephone number is (703) 308-1189.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Jon P. Weber, Ph.D. Primary Examiner Application No.: 10/036,371

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
	 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 			
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
	7. Other:			
Αp	plicant Must Provide:			
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".			
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.			
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).			
For	questions regarding compliance to these requirements, please contact:			
	Rules Interpretation, call (703) 308-4216			
For	CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA)			
ıaı	Technical Assistance703-287-0200			
	To Purchase Patentin Software 702 206 2000			

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE